DANVERS, Mass., Aug 18, 2008 (BUSINESS WIRE) -- Abiomed, Inc. (NASDAQ: ABMD) today announced the public offering
of 2,419,932 shares of its common stock. Morgan Stanley & Co.
Incorporated will be the sole underwriter for the offering.
The underwriter may offer the shares from time to time in one or
more transactions in the over-the-counter market or through negotiated
transactions at market prices or at negotiated prices. The offering is
being made pursuant to a shelf registration statement that became
effective on October 17, 2006.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall there
be any sale of the securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state. A prospectus
supplement relating to the offering will be filed with the Securities
and Exchange Commission. When available, copies of the prospectus
supplement and accompanying base prospectus may be obtained upon
request to Morgan Stanley & Co. Incorporated, 180 Varick Street, New
York, New York 10014, Attention Prospectus Department or by e-mail at
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading
provider of medical devices that provide circulatory support to acute
heart failure patients across the continuum of care in heart recovery.
Our products are designed to enable the heart to rest, heal and
recover by improving blood flow and/or performing the pumping of the
heart. For additional information please visit: www.abiomed.com.
Statements in this press release concerning the expected public
offering are "forward-looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to a number of
factors and uncertainties. Information contained in these
forward-looking statements is inherently uncertain, and actual
performance and results may differ materially. Such factors that could
cause actual results to differ materially from any forward-looking
statements made by Abiomed include, among others, the risk that the
planned public offering will not be completed, whether as a result of
potential disruptions in the capital markets, our failure to satisfy
any of the closing conditions in the underwriting agreement, or other
factors, and other risks and challenges detailed in the Company's
filings with the Securities and Exchange Commission, including the
Company's annual report on Form 10-K and most recently filed quarterly
report on Form 10-Q. Readers are cautioned not to place undue reliance
on any forward-looking statements, which speak only as of the date of
this Release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements that
may be made to reflect events or circumstances that occur after the
date of this Release or to reflect the occurrence of unanticipated
SOURCE: Abiomed, Inc.
Daniel J. Sutherby, 978-777-5410
Chief Financial Officer